Related Experiment Videos
Cephalexin in the treatment of upper respiratory tract infections
Insights
Cephalexin is an effective antibiotic for many pediatric and adult respiratory infections, showing results comparable to penicillin for strep throat. However, it is less effective against infections caused by Haemophilus influenzae.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Background:
- Cephalexin is a widely used semisynthetic cephalosporin antibiotic.
- It has established clinical applications in treating pediatric and adult respiratory tract infections.
Purpose of the Study:
- To evaluate the efficacy of cephalexin in various pediatric and adult respiratory infections.
- To compare cephalexin's effectiveness against other antibiotics like penicillin.
- To identify specific pathogens or conditions where cephalexin may be less effective.
Main Methods:
- Clinical assessment of treatment outcomes.
- Bacteriological cure rates were monitored.
- Incidence of relapse and reinfection was analyzed.
- Dosage efficacy was assessed in different age groups and infection types.
Main Results:
- Cephalexin demonstrated comparable efficacy to penicillin, cyclocillin, and cephaloglycin in treating pharyngitis and tonsillitis caused by beta-hemolytic streptococci.
- Effective in otitis media at 50-100 mg/kg/day, but with a 50% failure rate for Haemophilus influenzae infections.
- Generally effective in other upper respiratory tract infections, with noted exceptions for H. influenzae.
- Adverse effects were infrequent and primarily gastrointestinal or dermatological.
Conclusions:
- Cephalexin is a valuable antibiotic for common pediatric and adult respiratory infections, particularly streptococcal pharyngitis.
- Treatment failures are noted in infections caused by Haemophilus influenzae.
- Recommended dosages vary for children and adults, and adverse effects are generally mild and infrequent.
Abstract:
Cephalexin, a semisynthetic cephalosporin antibiotic, has wide clinical application in respiratory infections of children and adults. In pharyngitis and tonsillitis due to beta-haemolytic streptococci, it is comparable to penicillin, cyclocillin, and cephaloglycin, as measured by clinical response, bacteriological cure rate, and incidence of relapse and reinfection. In otitis media, it is effective at dosages of 50-100 mg/kg/day except in those infections caused by Haemophilus influenzae, in which there is failure in 50% of the cases. In other infections of the upper respiratory tract, it appears to be effective except, again, in those caused by H. influenzae. Dosages of 1-2 g/day have been used in adults and 20-100 mg/kg/day in children. Adverse effects, mostly gastrointestinal upsets, rash, and urticaria, have been relatively infrequent and have not required discontinuance of the drug.